Home › Research › Prevention and risk
The risks of long-term use of proton pump inhibitors: a critical review
Jaynes M, Kumar AB.. Therapeutic advances in drug safety, 2018-11-19
Topic: Risk, prevention and care in population studies
Plain-language summary
Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Their use is likely even higher than estimated due to an increase in the number of PPIs available without a prescription. Appropriate indications for PPI use include Helicobacter pylori infection, erosive esophagitis, gastric ulcers, and stress ulcer prevention in high-risk critically ill patients. Unfortunately, PPIs are often used off-label for extended periods of time. This increase in PPI usage over the past two decades has called into question the long-term effects of these medications. The association between PPI use and infection, particularly Clostridium difficile and pneumonia, has been the subject of several studies. It's proposed that the alteration in gastrointestinal microflora by PPIs produces an environment conducive to development of these types of infections. At least one study has suggested that long-term PPI use increases the risk of dementia. Drug interactions are an important and often overlooked consideration when prescribing any medication. The potential interaction between PPIs and antiplatelet agents has been the subject of multiple studies. One of the more recent concerns with PPI use is their role in the development or progression of chronic kidney disease. There is also some literature suggesting that PPIs contribute to the development of various micronutrient deficiencies. Most of the literature examining the potential adverse effects of PPI use is composed of retrospective, observation studies. There is a need for higher quality studies exploring this relationship.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that at least one study has suggested long-term proton pump inhibitor use increases the risk of dementia, among other concerns. It reports a suggested association, not a proven cause, and offers no treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jaynes, M., & Kumar, A. B. (2019). The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic advances in drug safety. https://doi.org/10.1177/2042098618809927
Vancouver
Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic advances in drug safety. 2019. doi:10.1177/2042098618809927. PMID: 31019676.
BibTeX
@article{jaynes2019-31019676,
author = {Jaynes, M. and Kumar, A. B.},
title = {{The risks of long-term use of proton pump inhibitors: a critical review}},
journal = {Therapeutic advances in drug safety},
year = {2019},
doi = {10.1177/2042098618809927},
pmid = {31019676},
url = {https://doi.org/10.1177/2042098618809927}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- At least one study has suggested that long-term PPI use increases the risk of dementia.
- There is also some literature suggesting that PPIs contribute to the development of various micronutrient deficiencies.
Why it matters
This review notes that at least one study has suggested long-term proton pump inhibitor use increases the risk of dementia, among other concerns. It reports a suggested association, not a proven cause, and offers no treatment or cure.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Therapeutic advances in drug safety) |
| Journal's citation record | 0 / 4 | Therapeutic Advances in Drug Safety: journal h-index 64 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 254 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 28.2 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 13.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 75 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Avinash B. Kumar: h-index 17 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Vanderbilt University: institution h-index 1,199 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31019676) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/2042098618809927
- PubMed: 31019676
- Original source →
- Free full text: Therapeutic Advances in Drug Safety →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.